129 related articles for article (PubMed ID: 15246631)
1. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
Fife KH; Wheeler CM; Koutsky LA; Barr E; Brown DR; Schiff MA; Kiviat NB; Jansen KU; Barber H; Smith JF; Tadesse A; Giacoletti K; Smith PR; Suhr G; Johnson DA
Vaccine; 2004 Jul; 22(21-22):2943-52. PubMed ID: 15246631
[TBL] [Abstract][Full Text] [Related]
2. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.
Brown DR; Fife KH; Wheeler CM; Koutsky LA; Lupinacci LM; Railkar R; Suhr G; Barr E; Dicello A; Li W; Smith JF; Tadesse A; Jansen KU
Vaccine; 2004 Jul; 22(21-22):2936-42. PubMed ID: 15246630
[TBL] [Abstract][Full Text] [Related]
3. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
4. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
5. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
Block SL; Nolan T; Sattler C; Barr E; Giacoletti KE; Marchant CD; Castellsagué X; Rusche SA; Lukac S; Bryan JT; Cavanaugh PF; Reisinger KS;
Pediatrics; 2006 Nov; 118(5):2135-45. PubMed ID: 17079588
[TBL] [Abstract][Full Text] [Related]
10. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
11. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
Nardelli-Haefliger D; Lurati F; Wirthner D; Spertini F; Schiller JT; Lowy DR; Ponci F; De Grandi P
Vaccine; 2005 May; 23(28):3634-41. PubMed ID: 15882523
[TBL] [Abstract][Full Text] [Related]
12. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
13. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
14. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
[TBL] [Abstract][Full Text] [Related]
16. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
Evans TG; Bonnez W; Rose RC; Koenig S; Demeter L; Suzich JA; O'Brien D; Campbell M; White WI; Balsley J; Reichman RC
J Infect Dis; 2001 May; 183(10):1485-93. PubMed ID: 11319684
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Mao C; Koutsky LA; Ault KA; Wheeler CM; Brown DR; Wiley DJ; Alvarez FB; Bautista OM; Jansen KU; Barr E
Obstet Gynecol; 2006 Jan; 107(1):18-27. PubMed ID: 16394035
[TBL] [Abstract][Full Text] [Related]
19. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]